Both Enbrel and Mirikizumab offer similar effectiveness in symptom control, with the main difference being how quickly they act. Either drug is a viable option depending on the patient’s needs.

Mirikizumab is gentler on the liver and kidneys and has a better safety profile for long-term use, particularly for older patients or those with pre-existing conditions.

Both Enbrel and Mirikizumab have a low risk of addiction when used correctly under medical supervision, with minimal potential for misuse.

Enbrel offers the convenience of a once-daily dose, simplifying treatment adherence for patients.

Mirikizumab is better for patients with cardiovascular or diabetes-related issues, as it has fewer interactions with other medications.

Both drugs offer advantages depending on treatment goals. Enbrel is great for fast relief, while Mirikizumab is better for long-term management. The choice depends on the patient’s specific needs.